Welcome
Quark Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that is a leader in the discovery and development of novel RNAi-based therapeutics. Quark has a fully integrated drug development platform.  Website Disclaimer...

QUARK is conducting  clinical studies in the areas of acute kidney injury associated with major cardiovascular surgery, dela...
Read More>
 
PF-655 (formerly REDD14NP and RTP801i) is a synthetic siRNA designed to inhibit the expression of Quark’s proprietary target, RTP801....
Read More>

QPI-1002 (I5NP) is a synthetic siRNA designed to temporarily inhibit expression of the pro-apoptotic protein, p53. Its development is...
Read More>

Development Pipeline...
Read More>
 
1/4/2012
Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007
 
5/3/2011
Rutgers Offers Hope in New Treatment for Spinal Cord Injuries
 
3/18/2011
In a Phase 2 Study PF-04523655 (RTP801I-14) Showed Improved Vision Over Standard of Care in Patients with Diabetic Macular Edema at 12 Months
More News >
Web Development HomeProductsContact ©2007 Quark Pharmaceuticals, Inc.